The diagnostic landscape is shifting toward high-sensitivity, automated technologies. Clinical diagnostics currently dominate the sector, accounting for 84.8% of the market share as of 2025. Cerebrospinal fluid analysis remains the leading fluid type, driven by the integration of automated immunoassay systems that standardize the monitoring of neurodegenerative diseases. These technological advancements allow laboratories to process higher volumes with greater precision while minimizing manual intervention.
Body fluid analysis market projected to reach $3.65 billion by 2031
The global body fluid analysis market is set for steady expansion, with projections indicating growth from $2.62 billion in 2026 to $3.65 billion by 2031. This 6.9% annual growth rate is fueled by an increasing clinical reliance on specialized diagnostics for neurological, infectious, and oncological conditions.
Consumables, including reagent kits and assay panels, represent the largest product segment at 70.4% market share. Because fluid analysis requires fresh reagents for every specimen, this segment benefits directly from rising test volumes. Meanwhile, the Asia-Pacific region is expected to lead global growth through 2031. Rapid healthcare modernization in China, Japan, and India is expanding laboratory capacity, while North America maintains its market position through mature infrastructure and established reimbursement pathways for biomarker assays. Major industry players, including Sysmex, Roche, and Abbott, continue to prioritize the development of multi-parameter testing to meet the demand for more comprehensive immunological characterization.
Comments (0)
No comments yet. Be the first!